Summary Exposure of ZR-75-1 human breast cancer cells for 48 h to human recombinant interferon alpha (IFNa) resulted in increased expression of oestrogen receptors as measured in a whole cell binding assay. This effect was inversely proportional to dose being significant following treatment with 10-1OOIUIFNml-l and was only observed at a low initial cell plating density. The extent of the increase in oestrogen receptor levels ranged from 1.2-to 7.2-fold following treatment with 1OIUIFNml-'. No increase in progesterone receptor expression was observed under the same experimental conditions. Concentrations of IFN which increased oestrogen receptor levels had no effect on cell proliferation. IFN (500 IU ml-1) inhibited cell proliferation and the combination of this treatment with tamoxifen (2piM) had a greater anti-proliferative effect than either drug alone although there was no evidence of synergism. However, a 5-day pretreatment of cells with IFN (10IUml-1) markedly sensitised them to the growth-inhibiting effect of a subsequent 6-day exposure to tamoxifen.
Anti-oestrogen therapy plays an increasingly important role in the management of patients with breast carcinoma. Although the mechanism of action of anti-oestrogens such as tamoxifen is incompletely understood, there is considerable evidence that the presence of a functional oestrogen receptor (ER) in the target tissue is important for the activity of such drugs in vitro, (Lippman et al., 1976) and in the clinic (Rose et al., 1985) .
In contrast to the proven efficacy of tamoxifen, clinical trials designed to assess the activity of human recombinant interferon, (IFN) towards breast cancer have yielded disappointing results (Sherwin et al., 1983; Nethersell et al., 1984) . Since many of the actions of the IFNs appear to involve enhanced expression of cellular differentiated functions (Taylor-Papadimitriou, 1985) , we considered the possibility that ER expression by human breast cancer might be enhanced by prior exposure of cells to IFN. Two recent studies have lent some support to this proposal. IFNax was reported to increase assayable ER when added directly to breast or uterine cell homogenates, (Dimitrov et al., 1984) , and increased ER and progesterone receptors (PGR) were detected in skin metastases in a small number of patients who had received fibroblast IFN for the treatment of advanced breast cancer (Pouillart et al., 1982) .
Confirmation of these data would further suggest that prior exposure of breast cancer cells to IFN might increase their sensitivity to tamoxifen. Such a drug combination would be attractive in the clinical setting given the relative lack of toxicity of the agents. Marth et al., (1985) failed to demonstrate any effect of IFNa 2 or IFNy on ER expression by MCF-7 or BT-20 human breast cancer cell lines whilst Sica et al., (1986) in a study reported simultaneously with our own preliminary data (van den Berg et al., 1986) , demonstrated enhanced ER and PGR expression in a subline of MCF-7 cells following IFNf treatment.
In this paper we have extended our earlier observations and report that IFNac 2 increases ER but not PGR expression in the ZR-75-1 human breast cancer cell line and that the effect on detectable ER is inversely proportional to dose and dependent on cell plating density. We have also investigated the consequences of IFN induced enhanced ER expression on the sensitivity of cells to the anti-proliferative effects of tamoxifen.
Materials and methods

Cells and culture conditions
The ZR-75-1 human breast cancer line was obtained from Flow Laboratories (Irvine, Scotland) and its human and mammary origin has been described previously (Lippman et al., 1977) . Cells were maintained routinely in RPMI 1640 medium supplemented with 5% foetal calf serum, 100IUml-I penicillin and 100,ugml-l streptomycin and grown in an air: CO2 atmosphere, (95:5 v/v), at 37°C.
Steroid hormone receptor assays ER and PGR expression were determined using a whole cell binding assay at 37°C similar to that described by OleaSerrano et al. (1985) . Cells, (10,000-200,000) were plated into 24 places multi-well dishes (Flow Laboratories, Irvine, Scotland) and allowed to attach for 24h. Medium was then replaced with medium containing 1% charcoal-stripped serum with or without the addition of 10-1000 IU ml-1 human recombinant IFNoa 2 arg, (kindly supplied by Bender & Co, Vienna, Austria). Receptor assays were performed 48 h later. The medium was removed and oestrogen or progesterone binding assessed using either a single concentration of ligand (I nM) or a range of concentrations for determination of maximal binding capacity (Bmax) and dissociation constant (Kd). Oestrogen (E2) binding was measured using (2, 4, 6, 7, 16, 17-3-H) C'ompetition binding assays The ability of IFN or tamoxifen to displace 3-H E2 from its binding sites was determined by incubating cells cultured as described above in the presence of 1 nM 3-H E2 together with IFN (10-1000 lUml-1) or tamoxifen (10-8-10-5M) for 1 h.
Inhibition of cell population growth The ability of IFN, tamoxifen or a combination of the two agents to inhibit the growth of ZR-75-1 cells was determined under the same conditions as used for receptor assays. Cells were initially plated at 50,000 cells/well and exposed to each drug singly or in combination continually for a 6-day period. In a separate group of experiments cells (10,000/well) were pre-exposed to IFN, (10 IU ml-1), for 5 days and then exposed to tamoxifen for a further 6 days. Cell number in drug-treated groups was expressed as a percentage of control cell number at day 6. Results Figure 1 shows the effect of a 2-day exposure to IFN on the binding of E2 (1 nM) to ZR-75-1 cells plated at two different cell densities. IFN had no significant effect on E2 binding to cells plated at a density of 200,000/well. However, when cells were initially plated at a density of 50,000/well prior exposure to IFN resulted in an increase in specific binding of E2 which was inversely proportional to the dose of IFN. This increase was significant following treatment with 100, 50 and 10 IU IFN ml -and was predominantly the result of an increase in total binding. In this experiment it was also noted that specific E2 binding in control cells, in comparison with that observed at the higher plating density, was lower than could be accounted for simply by the reduction in cell number. Figure 2 shows a Woolf plot obtained following exposure of control and IFN, (10IUml-1), treated cells to a range of 3-H E2 concentrations. IFN treatment resulted in a more than 2-fold increase in Bmax. In 3 separate experiments this effect of IFN was confirmed although expression of ER in control cells showed considerable variability (Table I) Figure 2 Woolf plot of H-E2 specific binding to ZR-75-1 cells. Cells were initially plated at 50,000/well. 0 Control; x 48h. pretreatment with IFN (I0 IU ml-1). ZR-75-1 cells over a 6-day period. Simultaneous exposure of cells to IFN (0lIUml-1), and tamoxifen (2pM) led to a small increase in anti-proliferative effect compared to tamoxifen alone but this was not significant. Cell proliferation was inhibited in cells continually exposed to 500 IUml-1 IFN and the combination of this concentration of IFN and 2pM tamoxifen was more growth inhibitory than either drug alone but again there was no evidence of synergism. Sensitisation of cells to the anti-proliferative effects of tamoxifen could be achieved if they were exposed to IFN (10IUml-1) for 5 days prior to anti-oestrogen treatment ( Figure 5 ). IFN alone again had no significant effect on cell proliferation whilst IFN pre-treatment reduced the cell number (as a percentage of control at day 6) of 2pM tamoxifen treated cells from 81+5% to 59+6%, (P<0.0 1).
Discussion
We have demonstrated that IFNa increases ER expression in the ZR-75-1 human breast cancer cell line. Similar results were reported for the activity of the IFN,B subtype towards an E2 supersensitive variant of the MCF-7 breast cancer cell line (Sica et al, 1986) . Our data further suggest that this effect of IFNa is only observed at low doses in the ZR-75-1 line and is dependent on a low initial cell plating density. In this respect our data are in agreement with those of Marth et al. (1985) who also failed to demonstrate any effect of IFNa (500 IU ml-1) on ER expression in this cell line or in the ER negative line BT-20. The reasons for the constraints on IFN effects on ER we have observed are presently unclear, although it is apparent that the anti-proliferative effects of IFNx are dissociated from its effect on ER expression (Figures 1 and 4) . ER expression in human breast cancer cells has been reported to be dependent on cell proliferation rate, with lower receptor levels being associated with rapidly dividing cells (Jakesz et al., 1984) . Under the experimental conditions described cells plated at 50,000/well grow exponentially whilst at 200,000/well virtual confluence is reached. It is possible, therefore, that IFN prevents this 'down regulation' of ER accompanying rapid cell proliferation. However, although control levels in cells plated at the lower density were occasionally low, considerable variability was observed although the effects of IFN were consistent (Table I) . Our data do not support the proposition that IFN causes an apparent increase in E2 binding through the formation of an IFN-ER-E2 complex (Dimitrov et al., 1984) since E2 binding was unchanged when the assay was performed in the presence of low concentrations of IFN (Figure 3) . However, since our data were obtained using a whole cell binding assay, it is probable that IFN would not gain access to intracellularily located ER.
We are currently investigating the effect of IFN on ER expression in the presence of cycloheximide and preliminary data indicate that ER levels are low in both control anl IFN treated cells, suggesting that intact protein synth sis is required for IFN induced enhanced ER expression.
The proposal that increased ER expression followinj IFN treatment represents a true increase in receptor numbers receives support from the observation that prior exposure to IFN increases the anti-proliferative effects of tamoxifen in this cell line ( Figure 5 ). The schedule of treatment is clearly critical since no synergism was apparent when IFN and tamoxifen were administered simultaneously (Figure 4) .
We have been unable to demonstrate an increase in PGR levels following IFN treatment (Sica et al., 1986 
